Tenders

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130 a Paragraph 8 Sgb V with the Active Ingredient Trastuzumab

Medicine Discount Contracts in Accordance with Section 130A Paragraph 8 Sgb V as Part of Open House Procedures

Medicines with the Active Ingredient Dapagliflozin (Atc: A10bk01)

Medicines with the Active Ingredient Interferon Beta-1A (Atc: L03ab07 - for Subcutaneous Use)

Drug Contracts with Accession Option

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredients Mentioned with the Possibility of Conclusion as Part of the So-Called Open House Procedure.

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Allergen Extract from Timothy Grass, Rye Grass, Etc. (Excl. Sut), Atc V01aa02 F. D. Z. 01.10.24-30.09.26

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Tocilizumab (Excl. Infusion Solution Concentrate), Atc L04ac07 (Obo) for the Period October 1St, 2024 - November 30Th, 2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V on Active Ingredients (Medicines) - Vv_79

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Baclofen (Excluding Oral Dosage Form), Atc M03bx01 (Obg) for the Period October 1St, 2024 - September 30Th, 2026